Compare HOFT & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HOFT | MDXH |
|---|---|---|
| Founded | 1924 | 2003 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Home Furnishings | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 144.6M | 149.0M |
| IPO Year | 1999 | 2021 |
| Metric | HOFT | MDXH |
|---|---|---|
| Price | $13.06 | $2.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.67 |
| AVG Volume (30 Days) | 26.7K | ★ 162.7K |
| Earning Date | 04-16-2026 | 05-13-2026 |
| Dividend Yield | ★ 3.41% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $397,465,000.00 | N/A |
| Revenue This Year | N/A | $30.78 |
| Revenue Next Year | $2.61 | $18.31 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.34 | $1.36 |
| 52 Week High | $15.99 | $5.33 |
| Indicator | HOFT | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 56.19 | 18.14 |
| Support Level | $9.22 | $1.90 |
| Resistance Level | $13.47 | $2.30 |
| Average True Range (ATR) | 0.71 | 0.21 |
| MACD | 0.17 | -0.10 |
| Stochastic Oscillator | 88.45 | 1.13 |
Hooker Furnishings Corp is a designer, marketer and importer of casegoods (wooden and metal furniture), leather furniture, fabric-upholstered furniture, lighting, accessories, and home decor for the residential, hospitality and contract markets. It is also domestically manufactured premium residential custom leather, custom fabric-upholstered furniture, and outdoor furniture. The company operates in four segment Hooker Branded segment, Home Meridian segment, Domestic Upholstery segment and All Other.
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.